IDO Targeting in Sarcoma: Biological and Clinical Implications

IDO Targeting in Sarcoma: Biological and Clinical Implications

Sarcomas are heterogeneous malignant mesenchymal neoplasms with limited sensitivity to immunotherapy. We recently demonstrated an increase in Kynurenine Pathway (KP) activity in the plasma of sarcoma patients treated with pembrolizumab. While the KP has already been described to favor immune escape...

Full description

Bibliographic Details
Main Authors: Imane Nafia, Maud Toulmonde, Doriane Bortolotto, Assia Chaibi, Dominique Bodet, Christophe Rey, Valerie Velasco, Claire B. Larmonier, Loïc Cerf, Julien Adam, François Le Loarer, Ariel Savina, Alban Bessede, Antoine Italiano
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-03-01
Series:Frontiers in Immunology
Subjects:
sarcomas
immunotherapy
indoleamine
kynurenine
PDL1
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.00274/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2020.00274/full

Similar Items